Finance Watch: Biopharma IPOs On The Upswing, Including Ex-US Offerings
Public Company Edition: Parabilis launched a record-breaking IPO in the US, but generics maker Apotex raised C$1.3bn ($930.7m) in Canada and Asia offerings continue. While follow-on deals are also keeping up a robust pace, Summit cited market conditions when nixing its offering.
Scrip - June 12, 2026

AstraZeneca Builds Up Oncology As It Looks To 2030
At an ASCO analyst briefing, the company highlighted programs in oncology and other disease areas that will help it meet a goal of bringing in $80bn in sales by 2030.
Scrip - June 12, 2026

Jazz’s Zepzelca Fails Another Second-Line SCLC Trial
Top-line data from the Phase III LAGOON study leave Zepzelca without confirmatory data for second-line treatment of small cell lung cancer, but first-line maintenance therapy remains the focus.
Scrip - June 12, 2026

Pfizer’s Legos Lays Out Oncology Focus And Direction
Pfizer oncology head Jeff Legos tells Scrip how program cuts and a sharper focus on ADCs, bispecifics and China partnerships have strengthened the company’s cancer pipeline.
Scrip - June 12, 2026

Pipeline Watch: Fourteen Approvals And Ten Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - June 12, 2026

EULAR: Levicept Believes It Has The New Humira On Its Hands
The UK biotech's chief scientific officer, Simon Westbrook, told Scrip at EULAR that LEVI-04's ability to target symptoms and potentially modify the disease could unlock a mega-blockbuster for osteoarthritis.
Scrip - June 12, 2026

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda
Q1 2026 saw Eli Lilly's Mounjaro displace Merck & Co.'s Keytruda as the world's best-selling drug by quarter. Seven of the top 10 products fell from Q4 2025, partly a seasonal first-quarter effect, but made the three who made gains all the more notable.
Scrip - June 12, 2026

LongBio’s Antibody Hits Phase III Endpoint In Seasonal Allergic Rhinitis
Chinese firm LongBio Pharma’s IgE-targeted antibody may become the first anti-IgE biologic for seasonal allergic rhinitis on the China market if approved following positive Phase III results.
Scrip - June 12, 2026

Why Big Pharma Should Pay Attention To GLP-1 Drug Use Insights From Brazil
As more big pharma firms join Novo Nordisk and Eli Lilly in the obesity drug race, they might want to pay attention to consumption patterns in Brazil, South America’s largest market, that are influencing commercial, legal and regulatory decisions.
Scrip - June 12, 2026

Wave Neuroscience Wins FDA Clearance For Personalized Brain Stimulation For PTSD
Wave Neuroscience announced today it received US FDA clearance for MeRT, a personalized TMS therapy that maps individual brainwave patterns via EEG to treat PTSD.
Medtech Insight - June 12, 2026

International Device Nomenclature Agency Calls On Regulators To Require GMDN Terms In Submissions
A new guide from the Global Medical Device Nomenclature Agency instructs regulators on the best approach for implementing the standardized device-naming system. The document calls for regulators to request GMDN Terms, as well as UDIs, in device submissions.
Medtech Insight - June 12, 2026

P&G Uses Consumer Data Sets, AI To Win On Digital Shelf – Chief Information Officer
P&G's chief information officer discusses how the company is deploying artificial intelligence and its vast consumer data to stay competitive in the digital marketplace.
HBW Insight - June 13, 2026

Livzon Gains Chinese Approval For Fertility Biosimilar
Livzon MABPharm has announced approval from China’s National Medical Products Administration for its recombinant human follitropin alfa solution for injection.
Generics Bulletin - June 12, 2026

Sanofi And Regeneron Signal ‘Vigorous’ Patent Defense Plans For Dupixent
Regeneron’s CFO Christopher Fenimore has outlined intentions to “extend Dupixent's marketing exclusivity for as long as we can,” as the list of upcoming biosimilar competitors keeps growing.
Generics Bulletin - June 12, 2026

Xbrane Bets On Partners To Unlock Darzalex Biosimilar
Xbrane has partnered with JOINN Biologics US to advance Xdarzane, its proposed Darzalex biosimilar, shifting further CMC and pilot-scale work to a specialist manufacturer as the Swedish developer pursues a capital-light strategy built around partnerships, licensing and retained upside.
Generics Bulletin - June 12, 2026

Streamlining Alone Will Not Fill Europe’s Biosimilar Void
Representatives from Medicines for Europe and its Biosimilar Medicines Group tell Generics Bulletin that Europe’s move away from routine comparative efficacy studies is a major step forward but not enough on its own to solve the looming biosimilar “void.”
Generics Bulletin - June 12, 2026

Fragile Scaling: The Hidden Risks When Biotech Cuts Its Way To Survival
While layoffs are treated most often as a financial lever, they are also a legal, operational and governance event that most biotechs fail to manage as such.
In Vivo - June 12, 2026